GT Biopharma Q2 Loss Narrows, But Going Concern and Nasdaq Delisting Risks Persist

summarizeSummary

GT Biopharma reported a narrower Q2 loss but reiterated going concern doubts, unremediated material weakness, and Nasdaq delisting risk. The stock trades at $0.295, far below the $1.00 minimum bid requirement.

check_boxKey Events · Earnings and Guidance · GTBP

• Q2 Loss Narrows

  Net loss of $4.5M for Q2 2026, down from $30.2M in Q2 2025, driven by absence of prior year's $28.7M Greenshoe Rights liability charge.

• Going Concern Warning

  Company reiterates substantial doubt about its ability to continue as a going concern; cash of $5.1M will not fund operations through the next twelve months without additional financing.

• Nasdaq Delisting Risk

  Stock price of $0.295 is far below the $1.00 minimum bid requirement; company has until November 16, 2026 to regain compliance or face delisting.

• Material Weakness Unremediated

  Disclosure controls and procedures remain ineffective due to a material weakness in accounting for complex financial transactions, first identified in 2025.

auto_awesomeAnalysis · GTBP · Life Sciences

GT Biopharma's Q2 2026 net loss narrowed to $4.5M from $30.2M a year ago, but the company reiterated its going concern warning and disclosed that cash will not fund operations through the next twelve months without additional financing. The stock trades at $0.295, far below the $1.00 Nasdaq minimum, and the company has until November 16, 2026 to regain compliance or face delisting. A material weakness in internal controls remains unremediated, and the Series L Preferred conversion price has been reset to the $0.454 floor, triggering anti-dilution adjustments that have increased warrant share counts to 57.5M. These factors create significant downside risk for existing shareholders.